Porton Recognized by LyncBio Therapeutics for ADC Payload-Linker CMC Capabilities

LYNC-101 is described by LyncBio as the first ADC for inflammatory bowel disease (IBD) to enter clinical development, with IND applications filed in both China and the United States. Designed to target activated immune cells and armed with a non-steroidal payload, the molecule precisely modulates immune signaling within inflamed tissues. Developed in-house on LyncBio's fourth-generation ADC platform, LYNC-101 has entered a Phase I trial in Australia, with preparations for additional global multicenter studies underway — offering IBD patients a more targeted therapeutic option.

At this critical stage of the LYNC-101 IND program, Porton, as the project's CDMO partner, completed process development and manufactured non-GMP toxicology batches and GMP clinical trial materials for LYNC-101's payload-linker. Facing tight production timelines and a complex synthetic route, Porton's development and manufacturing teams worked in close coordination to deliver:

• Accelerated development and delivery — optimized a multi-step synthetic route within six months, produced non-GMP and GMP batches in parallel, and completed delivery two months ahead of schedule;

• Yield breakthrough — process innovations at key steps substantially increased yields, securing a stable supply of Phase I clinical materials;

• Deviation-free GMP execution — no deviations were recorded during the GMP manufacturing campaign.

LyncBio highly commended Porton's innovative problem-solving, stringent quality standards, and exceptional execution throughout the project.
"The Porton team is more than a technically strong partner — they are a trusted ally," said Dr. Cexiong Fu, Founder and CEO of LyncBio. "Throughout the development of LYNC-101, Porton's expertise in process development, analytics, and manufacturing, combined with disciplined project management, built a solid quality foundation for our program. The team's dedication and sense of ownership gave us strong confidence as the program advanced, helping bring LYNC-101 to patients sooner."

"We are honored by this recognition from LyncBio," said Mr. Andrew Chen, VP and CFO of Porton. "It affirms not only the results we delivered on this project, but also the shared commitment behind our 'Customer First' values. The successful IND filing of LYNC-101 was the result of both teams working side by side. Building on our extensive experience with ADCs and payload-linkers, we will continue to provide highly efficient CMC support throughout LyncBio's clinical development, and we have full confidence in the future of this partnership."

Through sustained investment and accumulated expertise in new molecular modalities, Porton has established four integrated R&D and manufacturing sites across Minhang, Fengxian and Pudong in Shanghai and New Jersey in the United States, covering the full spectrum from drug substance to drug product and from development through commercial manufacturing, and continues to expand its high-potency manufacturing capacity. Looking ahead, Porton will continue to strengthen its capabilities in new modalities, leveraging standardized technical frameworks to reduce CMC development risks for its clients and enabling innovative biopharma companies worldwide to accelerate their drug candidates into the clinic — advancing the mission of enabling earlier access to good medicines.

About LyncBio Therapeutics

About Porton Biologics and Conjugates CDMO Platform